Strong progress for drug development company Evgen Pharma

Two research scientists looking at microscope slides

Strong progress for drug development company Evgen Pharma

Drug development company Evgen Pharma said it has “achieved a great deal” in recent months in the research and operational sides of the business.

Evgen, which operates from Wilmslow and Liverpool, develops medicines with a focus on cancer and respiratory diseases.

Dr Huw Jones, who joined as chief executive in October, said: “Substantial progress was made in the half year in business development and in particular in our STAR trial where patients with community acquired pneumonia from any infection including Covid-19 can be recruited.”

He said “preliminary pre-clinical data look compelling” for its next cancer indication as the company continues “to demonstrate the huge potential of our pipeline”.

Evgen’s core technology is Sulforadex, a method for synthesising and stabilising the naturally-occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.

Its lead product, SFX-01, has has been used to treat over 150 patients in clinical trials for advanced metastatic breast cancer.

The business recorded a £1.8m loss in the six months to September, which it said was in line with expectations, and had £2.3m cash at the end of the period.

In September it revealed it had agreed a licensing deal worth an initial £8m with biotech incubator Juvenescence. The payments are based on milestones, with royalties on sales, and the product is expected to be launched in two years’ time.

To access the article, please click here.

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.